New hope for babies with brain cancer: targeted drug trial
NCT ID NCT06528691
Summary
This study is testing how well the drug entrectinib works as the first treatment for children under 3 years old who have brain tumors with specific genetic changes (NTRK or ROS1 fusions). The goal is to see if the drug shrinks the tumors and helps children live longer without their cancer getting worse. Participants will take the drug daily for up to two years and be followed for five years to monitor their health.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
King Hussein Cancer Center
RECRUITINGAmman, 11941, Jordan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
St. Jude Children's Research Hospital
RECRUITINGMemphis, Tennessee, 38105, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.